Our data demonstrated that the highly expressed lymphocytic activation molecule family member 7 (CD319, also known as SLAMF7/CS1) on PCs was considerably more robust than CD138; enabled identification of myeloma PCs, including in samples that have been delayed or frozen (42); and was an effective target for new immunotherapies, including CAR T cells and monoclonal Abs (e.g., elotuzumab) (39, 43, 44). This evidence concerns the gene SLAMF7 and plasma cell myeloma.